Investigation the effects of cilostazol and rosuvastatin on kidney and heart: An experimental acute kidney and heart injury model

Abstract

ÖZAmaç: Bu çalışmada, deneysel bir modelde ameliyat öncesi silostazol ve rosuvastatin tedavisinin böbrek iskemi/reperfüzyon hasarına olan etkisi ve uzak kalp reperfüzyon hasarı üzerine olan etkisi araştırıldı.Ça lış mapla nı:Toplam 35 adet dişi Sprague-Dawley sıçan rastgele beş gruba ayrıldı (n=7). Median laparotomi yapılarak, her iki böbreğe 45 dakika süren iskemi uygulandı. Cerrahi girişimin üç gün öncesinden başlayarak oral tedavi uygulandı (20 mg/kg silostazol, 10 mg/kg rosuvastatin ve 20 mg/kg cilostazol + 10 mg/kg rosuvastatin). Cerrahi girişimden bir gün sonra ise kan örnekleri ve böbrek ve kalp doku örnekleri alındı. Bul gu lar:Böbrek dokularının immünhistokimyasal değerlendirmesinde tümör nekroz faktör-alfa ve hipoksi ile indüklenebilir faktör-1 alfa immünreaktivitesinin silostazol, rosuvastatin ve silostazol + rosuvastatin grubunda, iskemi/ reperfüzyon hasarı grubuna kıyasla anlamlı düzeyde daha düşük olduğu tespit edildi (p<0.05). Kalp dokularının immünhistokimyasal değerlendirmesinde tümör nekroz faktör-alfa immünreaktivitesi, iskemi/reperfüzyon hasarı grubuna kıyasla silostazol grubunda anlamlı düzeyde daha düşüktü. Hipoksi ile indüklenebilir faktör-1 alfa immünreaktivitesi, silostazol, rosuvastatin ve silostazol + rosuvastatin grubunda, iskemi/reperfüzyon hasarı grubuna kıyasla, anlamlı düzeyde daha düşüktü (p<0.05). İskemi/reperfüzyon hasarı grubuna kıyasla, silostazol, rosuvastatin ve silostazol + rosuvastatin grubunda, serum üre, kreatinin, kreatin kinaz-kas ve beyin ve troponin düzeyleri anlamlı düzeyde daha düşüktü (p<0.05).So nuç: Silostazol ve rosuvastatinin böbrek iskemi/reperfüzyon ve uzak kardiyak reperfüzyon hasarı üzerinde koruyucu etkileri olmakla birlikte, bu etki kombine tedaviye kıyasla silostazol tedavisi ile artabilir.Anah tarsöz cük ler: Kalp; iskemi/reperfüzyon hasarı, böbrek. ABSTRACTBackground: In this study, we aimed to assess the effects of preoperative cilostazol and rosuvastatin therapy on kidney ischemia/ reperfusion injury and remote cardiac reperfusion injury in an experimental model.

Direct kidney injury or lower extremity ischemia induced indirect kidney injury: Which one is more harmful for kidneys?

“…In their study, they reported the protective effects of the drugs on kidneys as well as cardiac muscle as a remote organ. 22 There are studies investigating the idea of reperfusion injury in specific tissues, as well as those investigating the protective effects of drugs following well studied animal IR models, but we have not seen any article in the literature trying to reveal the rate of kidney damage in two different settings: in the first setting, the IR was created in a remote organ, the lower extremity, and the injury in renal tissues was evaluated. In the second setting, the IR was created within the renal tissue and the injury was evaluated in the same tissue.…”

“…In their study, they reported the protective effects of the drugs on kidneys as well as cardiac muscle as a remote organ. 22…”

Protective effect of cilostazol and rosuvastatin on acute kidney injury-induced lung injury using TNF-a and HIF-1a immunoreactivities

“…In our previous study, we also showed similar results with this study and we showed beneficial effect of cilostazol on kidney I/R injury. [5] Gokce et al [15] designed a study to evaluate the effects of cilostazol and diltiazem to counter the nephrotoxicity-induced by the calcineurin inhibitor cyclosporine. They showed cilostazol and diltiazem were effective to decrease renal I/R injury.…”

“…The protective effect of rosuvastation was lower, compared to cilostazol or combined therapy. [5] In this study, we continued the same medication in the same animal group and we examined the beneficial effects of these drugs on lungs after kidney I/R injury. Based on our results, lung tissue examinations showed that HIF-1a immunoreactivity was decreased significantly in cilostazol, rosuvastatin, and combination group.…”

“…[3,4] In our previous study, we designed an acute kidney injury model and we showed that cilostazol and rosuvastatin had beneficial effects on preventing direct kidney I/R injury and direct kidney I/R injury-induced heart injury. [5] In the present experimental study, which is the continuation of our previous study, we aimed to investigate the protective effects of oral cilostazol, rosuvastatin, and their combination treatment against renal I/R-induced remote lung injury using immunohistochemical indicators.…”